CMP Pharma and Generic Specialty Pharma Sign Product Development Agreement
Farmville, NC – February 5, 2016 – CMP Pharma, Inc. of Farmville, NC and Generic Specialty Pharma Ltd. (GSP) of Dublin, Ireland have reached an agreement to partner on the development of a new prescription product (NDA). The product under development will be available in a sterile vial and represents CMP’s first product in an injectable dosage form.
Commenting on the agreement, CMP Pharma’s CEO Gerald Sakowski said “This agreement reinforces our commitment to bring new niche products to market. We are pleased that this product provides CMP a unique opportunity to expand into a new dosage form area while at the same time provides an important product to our current acute care customer base”.
CMP Pharma is a specialty pharmaceutical company located in Farmville, NC that develops and manufactures a portfolio of high-value topical and oral liquid pharmaceutical products. The company was founded in the early 1980s around the development of a ready-to-use liquid for sodium polystyrene sulfonate, a prescription drug used for the treatment of hyperkalemia.
Generic Specialty Pharma is a privately owned pharmaceutical company established in 2012, headquartered in Dublin, Ireland. GSP and its affiliates markets products through partners in more than 30 countries throughout the world with a strong focus on injectables.